vTv Therapeutics

$1.89
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.01 (-0.52%) Today

-$0.03 (-1.56%) As of 4:21 PM EST after-hours

Why Robinhood?

You can buy or sell VTVT and other stocks, options, and ETFs commission-free!

About VTVT

vTv Therapeutics Inc. Class A Common Stock, also called vTv Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC. The listed name for VTVT is vTv Therapeutics Inc. Class A Common Stock.

CEO

Stephen L. Holcombe

Employees

Headquarters

High Point, North Carolina

Founded

2015

Market Cap

97.51M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

614.45K

High Today

$1.97

Low Today

$1.87

Open Price

$1.96

Volume

457.16K

52 Week High

$4.23

52 Week Low

$1.44

Collections

VTVT Earnings

-$0.11

-$0.07

-$0.04

$0.00

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 18, After Hours